Form D · Pharmaceuticals
MPX Bioceutical Corp
Toronto, A6 · CIK 0001728215
Offering snapshot reported Jan 22, 2018 · SEC filing
- Reported sold
- $2.48M Offering amount: $2.48M
- Investors reported
- 20 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 19, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 22, 2018 | Initial | $2,480,000 | No comparison | 20 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-303844
Source: Form D, filed Jan 22, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| W. Scott Boyes | Director, Executive |
| Jeremy S. Budd | Executive |
| Robert R. Galvin | Director |
| David Mc Laren | Executive |
| Andrew R. Ryan | Director |
| Richard S. Segerblom | Director |
| Randall G. Stafford | Director |
| Elizabeth M. Stavola | Director, Executive |
| Miles D. Thompson | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
5255 Yonge Street, Suite 701
Toronto, A6, M2N 6P4
Toronto, A6, M2N 6P4